Health · 1 sources covering this

STAT+: Amylyx endocrine drug succeeds in pivotal study

In a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Amylyx endocrine drug succeeds in pivotal study
In a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/2bd363ede99e3b98d8617dd81504bb94097da305"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Amylyx endocrine drug succeeds in pivotal study"></iframe>

STAT+: Amylyx endocrine drug succeeds in pivotal study

How 1 sources are covering this

STAT+: Amylyx endocrine drug succeeds in pivotal study

More from Health

STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

What Geriatric Emergency Departments Do Differently

Drive for Nuclear Power Boosts Uranium Industry — And Tribal Health Concerns in Southwest

She told no one about her agony except ChatGPT. What her death reveals about AI risks

Reader

Trust & legal

Across the network